CA2230389A1 - Formulations containing melatonin to be topically applied for the purpose of protecting the skin from oxidative damage - Google Patents
Formulations containing melatonin to be topically applied for the purpose of protecting the skin from oxidative damage Download PDFInfo
- Publication number
- CA2230389A1 CA2230389A1 CA 2230389 CA2230389A CA2230389A1 CA 2230389 A1 CA2230389 A1 CA 2230389A1 CA 2230389 CA2230389 CA 2230389 CA 2230389 A CA2230389 A CA 2230389A CA 2230389 A1 CA2230389 A1 CA 2230389A1
- Authority
- CA
- Canada
- Prior art keywords
- melatonin
- skin
- cosmetic formulations
- inhibit
- damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 124
- 229960003987 melatonin Drugs 0.000 title claims abstract description 124
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 124
- 238000009472 formulation Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000004792 oxidative damage Effects 0.000 title claims abstract description 18
- 239000002537 cosmetic Substances 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 230000000475 sunscreen effect Effects 0.000 claims abstract description 13
- 239000000516 sunscreening agent Substances 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 11
- 230000035515 penetration Effects 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 230000002411 adverse Effects 0.000 claims abstract description 5
- 239000004909 Moisturizer Substances 0.000 claims abstract 2
- 230000001333 moisturizer Effects 0.000 claims abstract 2
- 210000003491 skin Anatomy 0.000 claims description 77
- 239000006210 lotion Substances 0.000 claims description 22
- 239000006071 cream Substances 0.000 claims description 21
- 239000003921 oil Substances 0.000 claims description 21
- 239000004615 ingredient Substances 0.000 claims description 20
- 239000002674 ointment Substances 0.000 claims description 20
- 102000009027 Albumins Human genes 0.000 claims description 13
- 108010088751 Albumins Proteins 0.000 claims description 13
- 102000003886 Glycoproteins Human genes 0.000 claims description 12
- 108090000288 Glycoproteins Proteins 0.000 claims description 12
- 230000003020 moisturizing effect Effects 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 210000004207 dermis Anatomy 0.000 claims description 4
- 210000002615 epidermis Anatomy 0.000 claims description 4
- 230000001766 physiological effect Effects 0.000 claims description 4
- 230000037380 skin damage Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 13
- 230000000996 additive effect Effects 0.000 claims 4
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 206010051246 Photodermatosis Diseases 0.000 claims 3
- 108091008324 binding proteins Proteins 0.000 claims 3
- 230000008845 photoaging Effects 0.000 claims 3
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 11
- 238000006731 degradation reaction Methods 0.000 abstract description 11
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 3
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- -1 sunblocks Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 206010042496 Sunburn Diseases 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000012404 Orosomucoid Human genes 0.000 description 2
- 108010061952 Orosomucoid Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020005124 DNA Adducts Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001950 radioprotection Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
A method is disclosed for the utilization of topically applied melatonin for the prevention of oxidative damage in human skin induced by sunlight; i.e., a method for preparing formulations containing melatonin for use as moisturizers, sunblocks, and sunscreens. In addition the formulations will contain one or more proteins that will preserve the melatonin from degradation while in storage, but will allow its controlled release for penetration into cells of the skin when topically applied to the skin, in such a manner that serum melatonin concentration is not raised to supra-physiological levels that may induce adverse effects. In addition the formulation may optionally contain other antioxidants and cosmetic agents.
Description
Page 2 of 8 I~ field of the invention.
This invention relates to the incorporation of melatonin into topically applied formulations for the purpose of preventing oxidative damage to the skin, in a manner that:
1 ) the melatonin is preserved in a stable form that maintains the anti-oxidative capability of the melatonin while it is in storage in the container for extended periods of time, and while it is exposed to the elements and sunlight for the period that it is applied to the skin, and;
1) the release of melatonin into the skin is restricted, so that the application to the skin of the formulations containing the melatonin does not induce an elevation of the concentration of melatonin in the serum to supra-physiological levels which might have adverse physiological effects.
Background In recent years, t:he awareness that oxidation contributes to damage to cells in the skin resulting in wrinkles, dryness and inelasticity, has led to the incorporation of many ingredients with known or presumed antioxidant effects. ~Chese include Vitamin A, Vitamin C, Vitamin E, and related compounds with similar chemical structures, as well as other organic materials such as tea, algae, and seaweeds .
It has recently been demonstrated that melatonin is a powerful antioxidant that can protect living mammalian cells from the toxic and damaging effects of oxidation (Reiter et al., 1997). An added advantage of melatonin over other antioxidants is that it readily passes through cell membranes, entc;rs cells and penetrates the nuclear membrane. Melatonin administration has been shown to reduce free radical induced damage to DNA associated with ionizing radiation in laboratory rodents (Vijayalaxmi et al., 1995 a, b). This ability of melatonin to reduce oxidative damage to DNA enhances natural repair mechanisms in the cells and may protect DNA in cells of the skin from mutations induced by solar radiation or other factors which may cause the cells to become malignant (Tan et al., 1994).
Because of the benefits which melatonin provides as an antioxidant, its use as a faod supplement has been proposed. Also important is the consideration that an antioxidant effect of melatonin could have an inhibitory effect on the incidence of development of melanomas.
Previous studies have reported an inhibitory effect of orally administered melatonin on the growth of melanomas already established in mice {Narita and Kudo, 1985) and in humans (McElhinney et al, 1994).
There are several factors that must be taken into account in order to incorporate melatonin into topically applied preparations/formulations. Firstly, it is important to maintain the melatonin in a stable state so that it will be effective as an antioxidant over the entire period of time that it is applied to the skin. Therefore, it is necessary that the formulation contain materials that prevent the degradation of melatonin while it is in storage in the container for extended periods oftime, at least months, and also for the period of time that it is exposed to the elements after being applied topically on the skin, which may be several hours.
Secondly, it is desirable to avoid rapid transdermal penetration in order to avoid greatly increasing circulating levels of melatonin in the serum, when applied over large areas of the skin. Unbound melatonin, when applied to the scalp or the forearm can increase circulating lever ~f melatonin in a dose dependent manner {Bangha et al., I 997).
Page 3 of 8 Summary We have determined that melatonin can be stabilized, and that its penetration into the skin can be restricted, by including albumin and/or a-1-acid glycoprotein in topically applied formulations. We propose to patent formulations that contain melatonin as an ingredient, including lotions, ointments, oils and creams and other topically applied substances used in cosmetics, for the purpose of moisturizing and/or preserving and maintaining skin texture. As well we propose to patent formulations that contain melatonin as an ingredient, including lotions, ointments, oils and creams, used for the purpose of protecting the skin from the effects of exposure to sunlight, commonly referred to as sun lotions, sun-screens or sun-blocks, which through a process of absorption by ingredients or by reflection by particles of substances such as titanium dioxide embedded in the lotions, ointments, oils, and creams, inhibit the ability of ultraviolet light (UV-A and/or UV-B )from reaching the skin.
Description of the invention We have determined that melatonin, because of it anti-oxidative properties, would provide two forms of protection to the skin when topically applied in a cream, lotion, ointment or oil. It would protect the skin by preserving the properties of skin from the effects commonly observed when people age, such as loss of elasticity and wrinkling. It would also reduce skin damage induced by exposure to sunlight.
Because of the nature of melatonin as a naturally occurring hormone, it must be protected during storage and must remain stable for the time that the product will remain on the skin.
Additionally, the release of melatonin from the topically applied formulation into the skin must be restricted so that the concentration in the skin does not significantly increase serum levels to a point where they might adversely influence normal physiological activity in the body.
We have determined that melatonin can be stabilized in a formulation, (oil, cream, lotion, ointment) in which it is dissolved by incorporating the proteins albumin and/or alpha-1-acid glycoprotein as components of the formulation. Utilizing the proteins albumin and alpha-1-acid glycoprotein as stabilizing agents to which melatonin can bind will help maintain the integrity of the anti-oxidizing properties of melatonin during storage. Because the binding of these proteins and melatonin is reversible, this will allow melatonin to be released in a controlled manner into the epidermis and dermis of the skin. For example, a phosphate buffer with 40%
propylene glycol can be used to enhance release of melatonin from proteins. This buffer has been shown to enhance the penetration into the skin of melatonin (Lee et al., 1994).
Page 4 of 8 The embodiments of this invention would consist of Topically applied formulations, including lotions, creams, ointments or oils, that claim to protect i:he skin against oxidative damage and that contain melatonin as an ingredient.
'Copically applied formulations, including lotions, creams, ointments or oils, that claim to protect t:he skin against oxidative damage and that contain melatonin, and a protein that reversibly binds to melatonin so as to stabilize and preserve it from degradation while in storage, but that will release the melatonin for penetration into cells ofthe skin when topically applied.
Topically applied formulations, including lotions, creams, ointments or oils, that claim to protect the skin against oxidative damage and that contain melatonin and albumin as ingredients.
Topically applied formulations, including lotions, creams, ointments or oils, that claim to protect t:he skin against oxidative damage and that contain melatonin and a-L-acid glycoprotein as ingredients.
'Copically applied formulations, including lotions, creams, ointments or oils, that claim to protect the skin against oxidative damage and that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation, and an ingredient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin as an ingredient.
i.e. moisturizing cosmetics containing melatonin.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin and a protein that reversibly binds to lnelatonin so as to stabilize and preserve it from degradation while in storage, but will allow its release for penetration into cells of the skin when topically applied. i.e.
moisturizing cosmetics that contain melatonin and a protein that reversibly binds to rnelatonin so as to stabilize and preserve it from degradation while in storage, but will release the melatonin for penetration into cells of the skin when topically applied.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin and albumin as ingredients. i.e.
moisturizing cosmetics containing melatonin and albumin.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin and a-1-acid glycoprotein as ingredients. i.e. moisturizing cosmetics containing melatonin and a-1-acid glycoprotein.
Page 5 of 8 Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and contain melatonin and a protein that reversibly hinds to melatonin so as to stabilize and preserve it from degradation, and an ingredient that will reverse the binding of m.elatonin from that protein during the time the formulation is applied to the skin.
i.e. moisturizing cosmetics containing contains melatonin and a protein that reversibly binds to melatonin so as to stabilize and preserve it from del,~radation while in storage and an ingredient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin as an ingredient.
i.e. cosmetics used as sunscreens or sunblocks that contain melatonin.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation while in storage, but that will allow its release for penetration into cells of the skin when topically applied. i.e .cosmetics used as sunscreens or sunblocks that contain melatonin and a protein that reversibly binds to metatonin so as to stabilize and preserve it from degradation while in storage, but that will release the melatonin for penetration into cells of the skin when topically applied.
Formulations, commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and albumin as ingredients.
i,e. cosmetics used as sunscreens or sunblocks that contain melatonin and albumin.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and a-1-acid glycoprotein as ingredients. i.e .cosmetics used as sunscreens or sunblocks that contain melatonin and a-1-acid glycoprotein.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, c»ntments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation, and an ingredient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin. i.e .cosmetics used as sunscreens or sunblocks that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation, and an in~,nedient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin.
Page 8 of 8 References l3angha, E., Lauth, D., Kistler, G. S., Elsner, P. 1997. Daytime serum levels of melatonin after topical application onto the human skin. Skin Pharmacol. 10:298-302.
McElhinney, D. B., Hoffmann, S. J., Robinson, W. A., Ferguson, J. 1994. Effect of melatonin on human skin colour. J. Invest. Dermatol. 102:258-259.
Morin, D., Simon, N., Depres-Brummer, P, Levi, F., Tillement, J, Uren, S.
1997. Melatonin high-affinity binding to alpha-I-acid glycoprotein in human serum.
Pharmacology 54:271-275.
Narita, T., Kudo, H. 1985. Effect of melatonin on B 16 melanoma growth in athymic mice.
Cancer Res. 45:4175-4177.
Reiter, R. J., Tang, L., Garcia, J. J. Munoz-Hoyos, A. 1997. Pharmacological actions of melatonin in oxygen radial pathophysiologry. Life Sci. 60:2255-271.
'Can, D. X., Reiter, R. J., Chen, L. D., Poeggeler, B., Manchester, L. C., Barlow-Walden, L. R.
I 994. Both physiological and pharmacological levels of melatonin reduce DNA
adduct formation induced by the carcinogen safrole.
Carcinogenesis 3 5:215-2l 8.
Vijayalaxmi, Reiter, R. J., Sewerynek, E., Poeggeler, B., Leal, B. Z., Meltz, M. 1995. Melatonin reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin. Radiat. Res. 143:102-106.
Vijayalaxmi, Reiter, R. J., Herman, T. S., Meltz, M. L. 1996.
Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutat. Res. 371:221-228.
This invention relates to the incorporation of melatonin into topically applied formulations for the purpose of preventing oxidative damage to the skin, in a manner that:
1 ) the melatonin is preserved in a stable form that maintains the anti-oxidative capability of the melatonin while it is in storage in the container for extended periods of time, and while it is exposed to the elements and sunlight for the period that it is applied to the skin, and;
1) the release of melatonin into the skin is restricted, so that the application to the skin of the formulations containing the melatonin does not induce an elevation of the concentration of melatonin in the serum to supra-physiological levels which might have adverse physiological effects.
Background In recent years, t:he awareness that oxidation contributes to damage to cells in the skin resulting in wrinkles, dryness and inelasticity, has led to the incorporation of many ingredients with known or presumed antioxidant effects. ~Chese include Vitamin A, Vitamin C, Vitamin E, and related compounds with similar chemical structures, as well as other organic materials such as tea, algae, and seaweeds .
It has recently been demonstrated that melatonin is a powerful antioxidant that can protect living mammalian cells from the toxic and damaging effects of oxidation (Reiter et al., 1997). An added advantage of melatonin over other antioxidants is that it readily passes through cell membranes, entc;rs cells and penetrates the nuclear membrane. Melatonin administration has been shown to reduce free radical induced damage to DNA associated with ionizing radiation in laboratory rodents (Vijayalaxmi et al., 1995 a, b). This ability of melatonin to reduce oxidative damage to DNA enhances natural repair mechanisms in the cells and may protect DNA in cells of the skin from mutations induced by solar radiation or other factors which may cause the cells to become malignant (Tan et al., 1994).
Because of the benefits which melatonin provides as an antioxidant, its use as a faod supplement has been proposed. Also important is the consideration that an antioxidant effect of melatonin could have an inhibitory effect on the incidence of development of melanomas.
Previous studies have reported an inhibitory effect of orally administered melatonin on the growth of melanomas already established in mice {Narita and Kudo, 1985) and in humans (McElhinney et al, 1994).
There are several factors that must be taken into account in order to incorporate melatonin into topically applied preparations/formulations. Firstly, it is important to maintain the melatonin in a stable state so that it will be effective as an antioxidant over the entire period of time that it is applied to the skin. Therefore, it is necessary that the formulation contain materials that prevent the degradation of melatonin while it is in storage in the container for extended periods oftime, at least months, and also for the period of time that it is exposed to the elements after being applied topically on the skin, which may be several hours.
Secondly, it is desirable to avoid rapid transdermal penetration in order to avoid greatly increasing circulating levels of melatonin in the serum, when applied over large areas of the skin. Unbound melatonin, when applied to the scalp or the forearm can increase circulating lever ~f melatonin in a dose dependent manner {Bangha et al., I 997).
Page 3 of 8 Summary We have determined that melatonin can be stabilized, and that its penetration into the skin can be restricted, by including albumin and/or a-1-acid glycoprotein in topically applied formulations. We propose to patent formulations that contain melatonin as an ingredient, including lotions, ointments, oils and creams and other topically applied substances used in cosmetics, for the purpose of moisturizing and/or preserving and maintaining skin texture. As well we propose to patent formulations that contain melatonin as an ingredient, including lotions, ointments, oils and creams, used for the purpose of protecting the skin from the effects of exposure to sunlight, commonly referred to as sun lotions, sun-screens or sun-blocks, which through a process of absorption by ingredients or by reflection by particles of substances such as titanium dioxide embedded in the lotions, ointments, oils, and creams, inhibit the ability of ultraviolet light (UV-A and/or UV-B )from reaching the skin.
Description of the invention We have determined that melatonin, because of it anti-oxidative properties, would provide two forms of protection to the skin when topically applied in a cream, lotion, ointment or oil. It would protect the skin by preserving the properties of skin from the effects commonly observed when people age, such as loss of elasticity and wrinkling. It would also reduce skin damage induced by exposure to sunlight.
Because of the nature of melatonin as a naturally occurring hormone, it must be protected during storage and must remain stable for the time that the product will remain on the skin.
Additionally, the release of melatonin from the topically applied formulation into the skin must be restricted so that the concentration in the skin does not significantly increase serum levels to a point where they might adversely influence normal physiological activity in the body.
We have determined that melatonin can be stabilized in a formulation, (oil, cream, lotion, ointment) in which it is dissolved by incorporating the proteins albumin and/or alpha-1-acid glycoprotein as components of the formulation. Utilizing the proteins albumin and alpha-1-acid glycoprotein as stabilizing agents to which melatonin can bind will help maintain the integrity of the anti-oxidizing properties of melatonin during storage. Because the binding of these proteins and melatonin is reversible, this will allow melatonin to be released in a controlled manner into the epidermis and dermis of the skin. For example, a phosphate buffer with 40%
propylene glycol can be used to enhance release of melatonin from proteins. This buffer has been shown to enhance the penetration into the skin of melatonin (Lee et al., 1994).
Page 4 of 8 The embodiments of this invention would consist of Topically applied formulations, including lotions, creams, ointments or oils, that claim to protect i:he skin against oxidative damage and that contain melatonin as an ingredient.
'Copically applied formulations, including lotions, creams, ointments or oils, that claim to protect t:he skin against oxidative damage and that contain melatonin, and a protein that reversibly binds to melatonin so as to stabilize and preserve it from degradation while in storage, but that will release the melatonin for penetration into cells ofthe skin when topically applied.
Topically applied formulations, including lotions, creams, ointments or oils, that claim to protect the skin against oxidative damage and that contain melatonin and albumin as ingredients.
Topically applied formulations, including lotions, creams, ointments or oils, that claim to protect t:he skin against oxidative damage and that contain melatonin and a-L-acid glycoprotein as ingredients.
'Copically applied formulations, including lotions, creams, ointments or oils, that claim to protect the skin against oxidative damage and that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation, and an ingredient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin as an ingredient.
i.e. moisturizing cosmetics containing melatonin.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin and a protein that reversibly binds to lnelatonin so as to stabilize and preserve it from degradation while in storage, but will allow its release for penetration into cells of the skin when topically applied. i.e.
moisturizing cosmetics that contain melatonin and a protein that reversibly binds to rnelatonin so as to stabilize and preserve it from degradation while in storage, but will release the melatonin for penetration into cells of the skin when topically applied.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin and albumin as ingredients. i.e.
moisturizing cosmetics containing melatonin and albumin.
Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and that contain melatonin and a-1-acid glycoprotein as ingredients. i.e. moisturizing cosmetics containing melatonin and a-1-acid glycoprotein.
Page 5 of 8 Formulations, including lotions, creams, ointments or oils, that are topically applied for the purpose of moisturizing the skin and contain melatonin and a protein that reversibly hinds to melatonin so as to stabilize and preserve it from degradation, and an ingredient that will reverse the binding of m.elatonin from that protein during the time the formulation is applied to the skin.
i.e. moisturizing cosmetics containing contains melatonin and a protein that reversibly binds to melatonin so as to stabilize and preserve it from del,~radation while in storage and an ingredient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin as an ingredient.
i.e. cosmetics used as sunscreens or sunblocks that contain melatonin.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation while in storage, but that will allow its release for penetration into cells of the skin when topically applied. i.e .cosmetics used as sunscreens or sunblocks that contain melatonin and a protein that reversibly binds to metatonin so as to stabilize and preserve it from degradation while in storage, but that will release the melatonin for penetration into cells of the skin when topically applied.
Formulations, commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and albumin as ingredients.
i,e. cosmetics used as sunscreens or sunblocks that contain melatonin and albumin.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, ointments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and a-1-acid glycoprotein as ingredients. i.e .cosmetics used as sunscreens or sunblocks that contain melatonin and a-1-acid glycoprotein.
Formulations commonly referred to as sunscreens or sunblocks, including lotions, creams, c»ntments or oils, that are topically applied for the purpose of inhibiting, or preventing, or providing relief from, the effects of sunlight on the skin, (including sunburn, dryness, itching, and physical damage to the cells of the skin), that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation, and an ingredient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin. i.e .cosmetics used as sunscreens or sunblocks that contain melatonin and a protein that reversibly binds to melatonin so as to stabilize it and preserve it from degradation, and an in~,nedient that will reverse the binding of melatonin from that protein during the time the formulation is applied to the skin.
Page 8 of 8 References l3angha, E., Lauth, D., Kistler, G. S., Elsner, P. 1997. Daytime serum levels of melatonin after topical application onto the human skin. Skin Pharmacol. 10:298-302.
McElhinney, D. B., Hoffmann, S. J., Robinson, W. A., Ferguson, J. 1994. Effect of melatonin on human skin colour. J. Invest. Dermatol. 102:258-259.
Morin, D., Simon, N., Depres-Brummer, P, Levi, F., Tillement, J, Uren, S.
1997. Melatonin high-affinity binding to alpha-I-acid glycoprotein in human serum.
Pharmacology 54:271-275.
Narita, T., Kudo, H. 1985. Effect of melatonin on B 16 melanoma growth in athymic mice.
Cancer Res. 45:4175-4177.
Reiter, R. J., Tang, L., Garcia, J. J. Munoz-Hoyos, A. 1997. Pharmacological actions of melatonin in oxygen radial pathophysiologry. Life Sci. 60:2255-271.
'Can, D. X., Reiter, R. J., Chen, L. D., Poeggeler, B., Manchester, L. C., Barlow-Walden, L. R.
I 994. Both physiological and pharmacological levels of melatonin reduce DNA
adduct formation induced by the carcinogen safrole.
Carcinogenesis 3 5:215-2l 8.
Vijayalaxmi, Reiter, R. J., Sewerynek, E., Poeggeler, B., Leal, B. Z., Meltz, M. 1995. Melatonin reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin. Radiat. Res. 143:102-106.
Vijayalaxmi, Reiter, R. J., Herman, T. S., Meltz, M. L. 1996.
Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutat. Res. 371:221-228.
Claims (21)
1. Cosmetic formulations, including lotions, creams, ointments or oils, and including preparations commonly termed moisturizers consisting of products topically applied to human skin for the purpose of moisturizing and preserving the skin from the effects commonly observed when people age, such as loss of elasticity and wrinkling., and including preparations termed sunscreens and sunblocks, consisting of products topically applied to the skin for the purpose of protecting the skin from damage induced by exposure to sunlight, that contain melatonin.
2. Cosmetic formulations as defined in claim 1, that contain a combination of melatonin and a protein that binds to and stabilizes melatonin for the period that it is in storage in a container prior to application to the skin as well as for the period that it is exposed to the elements while on the skin.
3. Cosmetic formulations as defined in claim 1, that contain a combination of melatonin and a protein that binds to and stabilizes melatonin, and thus restricts diffusion of melatonin through the skin, so that the application to the skin of the formulations containing the melatonin does not induce an elevation of the concentration of melatonin in the serum to supra-physiological levels, which might have adverse physiological effects.
4. Cosmetic formulations as defined in claim 1, that contain a combination of melatonin, a protein that binds melatonin, and an ingredient that will promote the release of melatonin from that binding protein so that the melatonin can penetrate into the skin during the time the cosmetic formulation is applied to the skin.
5. Cosmetic formulations as defined in claim 1, that include melatonin as an additive, to prevent the oxidative damage to the skin.
6. Cosmetic formulations as defined in claim 1, that include melatonin as an additive in to inhibit the damage associated with photoaging.
7. Cosmetic formulations as defined in claim 1, that include melatonin as an additive to inhibit sunlight induced oxidative damage to the skin.
8. Cosmetic formulations as defined in claim 1, that include melatonin as an additive to inhibit sunlight induced oxidative damage to DNA in cells of the dermis and epidermis of the skin.
9. Cosmetic formulations as defined in claim 1, that include melatonin to inhibit ultraviolet irradiation-induced skin damage.
10.Cosmetic formulations as defined in claim 1, that include melatonin and albumin as additives to prevent the oxidative damage induced by sunlight.
Page 7 of 8
Page 7 of 8
11.Cosmetic formulations as defined in claim 1, that include melatonin and albumin as additives to inhibit the damage associated with photoaging.
12.Cosmetic formulations as defined in claim 1, that include melatonin and albumin as additives to inhibit sunlight induced oxidative damage to the skin.
13. Cosmetic formulations as defined in claim 1, that include melatonin and albumin as additives to inhibit sunlight induced oxidative damage to DNA in cells of the dermis and epidermis of the skin.
14. Cosmetic formulations as defined in claim 1, that include melatonin and albumin as additives to inhibit ultraviolet irradiation-induced skin damage.
15. Cosmetic formulations as defined in claim 1, that include melatonin and .alpha.-1-acid glycoprotein as additives to prevent the oxidative damage induced by sunlight.
16. Cosmetic formulations as defined in claim 1, that include melatonin and .alpha.-1-acid glycoprotein as additives to inhibit the damage associated with photoaging.
17. Cosmetic formulations as defined in claim 1, that includes melatonin and .alpha.-1-acid glycoprotein as additives to inhibit sunlight induced oxidative damage to the skin.
18. Cosmetic formulations as defined in claim 1, that include melatonin and .alpha.-1-acid glycoprotein as additives to inhibit sunlight induced oxidative damage to DNA
in cells of the dermis and epidermis of the skin.
in cells of the dermis and epidermis of the skin.
19. Cosmetic formulations as defined in claim 1, that include melatonin and .alpha.-1-acid glycoprotein to inhibit ultraviolet irradiation-induced skin damage.
20. Cosmetic formulations as defined in claim 1, that contain a combination of melatonin and a protein that binds to and stabilizes melatonin while it is in storage, and an ingredient that will promote the release of melatonin from that binding protein when it is applied to the skin in order to regulate the rate of penetration of melatonin into the skin during the time the formulation is applied to the skin.
21. Cosmetic formulations as defined in claim 1, that contain a combination of melatonin and a protein that binds to and stabilizes melatonin, and an ingredient that will promote the release of melatonin from that binding protein in order to regulate the rate of penetration of melatonin into the skin during the time the formulation is applied to the skin, so that the application to the skin of the formulations containing the melatonin does not induce an elevation of the concentration of melatonin in the serum to supra-physiological levels, which might have adverse physiological effects, but does promote the absorption of melatonin into the skin at levels that the anti-oxidative properties of melatonin will be effective.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2230389 CA2230389A1 (en) | 1998-04-28 | 1998-04-28 | Formulations containing melatonin to be topically applied for the purpose of protecting the skin from oxidative damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2230389 CA2230389A1 (en) | 1998-04-28 | 1998-04-28 | Formulations containing melatonin to be topically applied for the purpose of protecting the skin from oxidative damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2230389A1 true CA2230389A1 (en) | 1999-10-28 |
Family
ID=29409332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2230389 Abandoned CA2230389A1 (en) | 1998-04-28 | 1998-04-28 | Formulations containing melatonin to be topically applied for the purpose of protecting the skin from oxidative damage |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2230389A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1369107A1 (en) * | 2002-06-03 | 2003-12-10 | Jan Marini Skin Research Inc. | Cosmetic skin care compositions |
| US20110206792A1 (en) * | 2008-10-23 | 2011-08-25 | Matteo Tutino | Compositions comprising vitamins |
| WO2012130609A1 (en) * | 2011-04-01 | 2012-10-04 | Iasomai Ab | New combination comprising n-acetyl-l-cysteine and its use |
| US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
| US11596620B2 (en) | 2013-03-13 | 2023-03-07 | F. Hoffmann-La Roche Ag | Formulations with reduced oxidation |
-
1998
- 1998-04-28 CA CA 2230389 patent/CA2230389A1/en not_active Abandoned
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1369107A1 (en) * | 2002-06-03 | 2003-12-10 | Jan Marini Skin Research Inc. | Cosmetic skin care compositions |
| US20110206792A1 (en) * | 2008-10-23 | 2011-08-25 | Matteo Tutino | Compositions comprising vitamins |
| WO2012130609A1 (en) * | 2011-04-01 | 2012-10-04 | Iasomai Ab | New combination comprising n-acetyl-l-cysteine and its use |
| AU2012237327B2 (en) * | 2011-04-01 | 2016-10-20 | Iasomai Ab | New combination comprising N-acetyl-L-cysteine and its use |
| US10300038B2 (en) | 2011-04-01 | 2019-05-28 | Iasomai Ab | Combination comprising N-acetyl-L-cysteine and its use |
| US11207287B2 (en) | 2011-04-01 | 2021-12-28 | Iasomai Ab | Combination comprising N-acetyl-L-cysteine and its use |
| US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
| US11596620B2 (en) | 2013-03-13 | 2023-03-07 | F. Hoffmann-La Roche Ag | Formulations with reduced oxidation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100638536B1 (en) | Compositions for Hair and / or Scalp | |
| EP0216084B1 (en) | Improved sunscreen and moisturizer | |
| TW477706B (en) | Skin tanning compositions and method | |
| JP5960123B2 (en) | Personal care composition | |
| US20120065261A1 (en) | Creatine compositions for skin treatment | |
| US20240148623A1 (en) | Gadusol and gadusporine compound formulations for topicals | |
| EP2627306B1 (en) | A sunscreen composition | |
| JPH05186324A (en) | Beautifying cosmetic | |
| JPH0892057A (en) | Cosmetic blended with extract of seed of coffee tree | |
| CN116059127B (en) | Natural sun-screening composition and preparation method and application thereof | |
| EP3122321B1 (en) | Photostable sunscreen composition for topical application | |
| CA2230389A1 (en) | Formulations containing melatonin to be topically applied for the purpose of protecting the skin from oxidative damage | |
| KR20130052379A (en) | Cosmetics composition for skin lightening color, antioxidantsand and method for preparing the same | |
| KR102012798B1 (en) | Synergistic compositions that reduce uv-induced lipid peroxidation, formulations and related methods | |
| AU744295B2 (en) | Composition and method for treatment of aging skin | |
| JPH11349435A (en) | Skin agent used for external use and effective for preventing and improving pigmentary symptom caused by ultraviolet light | |
| JPH08337510A (en) | Melanin production inhibitor | |
| CN115177565B (en) | Whitening and skin brightening composition and application thereof in cosmetics | |
| US6551581B1 (en) | Methods for improving the aesthetic appearance of skin and hair | |
| EP1416911B1 (en) | Personal care compositions | |
| JPH08104616A (en) | Cosmetic having both antisuntan and beautifying effects | |
| JP2002370962A (en) | Bleaching preparation and cosmetic for preventing and improving aging of skin | |
| AU723856B2 (en) | Sunscreen compositions containing damaged RNA fragments | |
| US9815783B2 (en) | (3-alkylthio)propenoic acid-derived compounds and their application in cosmetics | |
| JP2006526585A (en) | Cosmetic skin lightening composition comprising an extract of a plant from the family Hyderaceae or Rubiaceae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |